QRxPharma enters into LOA with Actavis
As per the agreement, Actavis has exclusive rights to commercialize and further develop MoxDuo IR for the US market. Actavis will assume all costs for product launch as
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.